{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=17",
    "query": {
      "condition": "Vector",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 687,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Vector&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T00:14:13.585Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03583606",
      "title": "A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ebola Disease",
        "Immunisation"
      ],
      "interventions": [
        {
          "name": "ChAd3-EBO-Z",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA Multi-Filo Ebola Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-11-12",
      "completion_date": "2020-01-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-29",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03583606"
    },
    {
      "nct_id": "NCT00955006",
      "title": "Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VRC-HIVDNA-016-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "VRCHIVADV014-00-VP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 17,
      "start_date": "2011-05",
      "completion_date": "2017-11-22",
      "has_results": false,
      "last_update_posted_date": "2021-10-14",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00955006"
    },
    {
      "nct_id": "NCT03065192",
      "title": "Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Idiopathic Parkinson's Disease",
        "Parkinson's Disease",
        "Basal Ganglia Disease",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Movement Disorders",
        "Nervous System Diseases",
        "Neurodegenerative Diseases",
        "Parkinsonian Disorders"
      ],
      "interventions": [
        {
          "name": "VY-AADC01",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 16,
      "start_date": "2017-05-11",
      "completion_date": "2021-08-10",
      "has_results": false,
      "last_update_posted_date": "2022-03-21",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03065192"
    },
    {
      "nct_id": "NCT00358761",
      "title": "Investigation of Southern Tick-Associated Rash Illness (STARI)",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Southern Tick-Associated Rash Illness"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2006-07-20",
      "completion_date": "2012-12-11",
      "has_results": false,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00358761"
    },
    {
      "nct_id": "NCT00097396",
      "title": "Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pneumonic Plague",
        "Preventive Therapy"
      ],
      "interventions": [
        {
          "name": "rF1V vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "DynPort Vaccine Company LLC, A GDIT Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 40,
      "start_date": "2004-11",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2011-06-30",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097396"
    },
    {
      "nct_id": "NCT00292942",
      "title": "Study of the Safety of Intravenous Artesunate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malaria",
        "Malaria, Cerebral"
      ],
      "interventions": [
        {
          "name": "Intravenous Artesunate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 26,
      "start_date": "2006-06-12",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2018-10-25",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00292942"
    },
    {
      "nct_id": "NCT04648046",
      "title": "CAR-T Cells for HIV Infection",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "LVgp120duoCAR-T cells, low dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LVgp120duoCAR-T cells, high dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Analytic Treatment Interruption",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Steven Deeks",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 11,
      "start_date": "2021-03-01",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 2,
      "location_summary": "Sacramento, California • San Francisco, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04648046"
    },
    {
      "nct_id": "NCT02061358",
      "title": "Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Viral Infection"
      ],
      "interventions": [
        {
          "name": "UV-4B 3 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 10 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 30 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 90 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 180 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 360 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 720 mg",
          "type": "DRUG"
        },
        {
          "name": "UV-4B 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emergent BioSolutions",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061358"
    },
    {
      "nct_id": "NCT01502735",
      "title": "Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "DENV-1 PIV, 2.5 µg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DENV-1 PIV, 5 µg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-12",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-04-22",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01502735"
    },
    {
      "nct_id": "NCT00428935",
      "title": "Safety Study of Mini-dystrophin Gene to Treat Duchenne Muscular Dystrophy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "rAAV2.5-CMV-minidystrophin (d3990)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "15 Years",
        "sex": "MALE",
        "summary": "5 Years to 15 Years · Male only"
      },
      "enrollment_count": 6,
      "start_date": "2006-03",
      "completion_date": "2010-07",
      "has_results": false,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-10-24T00:14:13.585Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00428935"
    }
  ]
}